Sartorius Stedim Biotech will supply equipment for Penn State’s new Fermentation Facility in the university’s Center of Excellence in Industrial Biotechnology.
Sartorius Stedim Biotech and Penn State University have entered into a collaborative partnership to advance multidisciplinary teaching and research in biotechnology, the company and university announced in an April 16, 2018 press release. This long-term relationship will support the education and preparation of the next generation of biotechnology leaders. Part of Sartorius’ investment will be to enhance the Fermentation Facility that will play a significant role in Penn State’s Center of Excellence in Industrial Biotechnology (CoEIB). Sartorius will provide fermentation technologies, and a central laboratory within the Fermentation Facility will be named the Sartorius Fermentation Gallery.
Sartorius views this partnership as an opportunity to create a hub that will promote innovation in biotechnology. “We look forward to bringing together future thought leaders within the new Sartorius Fermentation Gallery,” said Reinhard Vogt, member of Executive Committee of Sartorius Stedim Biotech, in the press release.
Sartorius, together with additional industry partners, has been supporting Penn State for more than a year in designing the new lab space and in equipping it based on the latest technologies. The Fermentation Facility is one of 10 core facilities in the Huck Institutes of the Life Sciences and the cornerstone of Penn State’s comprehensive biotechnology effort. This effort includes the CoEIB, recently launched with a landmark gift from CSL Behring. The CoEIB provides a focal point for Penn State’s programs in the area of industrial biotechnology, including the development of research and educational initiatives focused, among other areas, on biopharmaceutical manufacturing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.